MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 2, 2014, Pages 155-161

  Yu, Qian Qian ^a   Wu, Hao ^a   Huang, Xiang ^a   Shen, Hua ^a   Shu, Yong Qian ^a   Zhang, Bin ^a   Xiang, Cheng Cheng ^a   Yu, Shao Min ^a   Guo, Ren Hua ^a   Chen, Liang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A549; Gene therapy; MicroRNA; MiR 1; Non small cell lung cancer; PIK3CA

Indexed keywords

MICRORNA 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN KINASE B; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL COUNTING; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

A549; GENE THERAPY; MICRORNA; MIR-1; NON-SMALL CELL LUNG CANCER; PIK3CA;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FLOW CYTOMETRY; GENES, REPORTER; GENES, TUMOR SUPPRESSOR; HUMANS; LUCIFERASES, RENILLA; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; PLASMIDS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84897068200     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.01.005     Document Type: Article

References (39)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Rueth N.M., Parsons H.M., Habermann E.B., Groth S.S., Virnig B.A., Tuttle T.M., et al. The long-term impact of surgical complications after resection of stage I non-small cell lung cancer: a population-based survival analysis. Ann Surg 2011, 254:368-374.
3. Nakamura H., Taniguchi Y., Miwa K., Adachi Y., Fujioka S., Haruki T., et al. Comparison of the surgical outcomes of thoracoscopic lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell lung cancer. Thorac Cardiovasc Surg 2011, 59:137-141.
4. Saxena S., Jonsson Z.O., Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003, 278:44312-44319.
5. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
6. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
7. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
8. Kent O.A., Mendell J.T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
9. Voorhoeve P.M., le Sage C., Schrier M., Gillis A.J., Stoop H., Nagel R., et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124:1169-1181.
10. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
11. Lee Y.S., Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007, 21:1025-1030.
12. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
13. Nasser M.W., Datta J., Nuovo G., Kutay H., Motiwala T., Majumder S., et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008, 283:33394-33405.
14. Nohata N., Sone Y., Hanazawa T., Fuse M., Kikkawa N., Yoshino H., et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2011, 2:29-42.
15. Migliore C., Martin V., Leoni V.P., Restivo A., Atzori L., Petrelli A., et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res 2012, 18:737-747.
16. Kojima S., Chiyomaru T., Kawakami K., Yoshino H., Enokida H., Nohata N., et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 2012, 106:405-413.
17. Hudson R.S., Yi M., Esposito D., Watkins S.K., Hurwitz A.A., Yfantis H.G., et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012, 40:3689-3703.
18. Yoshino H., Enokida H., Chiyomaru T., Tatarano S., Hidaka H., Yamasaki T., et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun 2012, 417:588-593.
19. Leone V., D'Angelo D., Rubio I., de Freitas P.M., Federico A., Colamaio M., et al. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab 2011, 96:E1388-E1398.
20. Yan D., Dong X.E., Chen X., Wang L., Lu C., Wang J., et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009, 284:29596-29604.
21. Datta J., Kutay H., Nasser M.W., Nuovo G.J., Wang B., Majumder S., et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008, 68:5049-5058.
22. Zhou X., Tan M., Stone H.V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
23. Roymans D., Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 2001, 268:487-498.
24. Massion P.P., Taflan P.M., Shyr Y., Rahman S.M., Yildiz P., Shakthour B., et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004, 170:1088-1094.
25. Wu C.D., Kuo Y.S., Wu H.C., Lin C.T. MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. J Biomed Sci 2011, 18:80.
26. Nohata N., Hanazawa T., Kikkawa N., Sakurai D., Sasaki K., Chiyomaru T., et al. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol 2011, 39:1099-1107.
27. Boeri M., Pastorino U., Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J 2012, 18:268-274.
28. Zhao Y., Samal E., Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214-220.
29. Chen J.F., Mandel E.M., Thomson J.M., Wu Q., Callis T.E., Hammond S.M., et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38:228-233.
30. Kwon C., Han Z., Olson E.N., Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci USA 2005, 102:18986-18991.
31. Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721-1726.
32. Tominaga E., Yuasa K., Shimazaki S., Hijikata T. MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res 2013, 319:77-88.
33. Zhao Q., Gu Y.J., Chen L., Zhang B., Liu C.P., Guo R.H. Expression and clinical significance of miR-1 and PIK3CA in NSCLC. Zhong Hua Lin Chuang Yi Shi Za Zhi 2013, 7:3367-3371. [Chinese].
34. Vanhaesebroeck B., Stein R.C., Waterfield M.D. The study of phosphoinositide 3-kinase function. Cancer Surv 1996, 27:249-270.
35. Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J., Frech M., et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997, 272:31515-31524.
36. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
37. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
38. Ulukus E.C., Kargi H.A., Sis B., Lebe B., Oztop I., Akkoclu A., et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Immunohistochem Mol Morphol 2007, 15:31-37.
39. Zhao P., Meng Q., Liu L.Z., You Y.P., Liu N., Jiang B.H. Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun 2010, 395:219-224.